Daria Hazuda

Daria Hazuda, Ph.D., serves as head of infectious disease and vaccine research at Generate:Biomedicines, leading the research team in identifying and prioritizing the best applications of The Generate Platform in vaccines and infectious diseases. 

Most recently, Daria was the vice president of infectious disease and vaccines and chief scientific officer of the Merck Cambridge Research site. Over her 30 year career at Merck, she held various positions of increasing responsibility within both the research and medical affairs organizations, managing cross-functional research teams covering antibiotic, antiviral and vaccine research, neuroscience discovery and innovative platform development teams. She led teams to discover and develop multiple drugs that have been approved, including antivirals for HIV, hepatitis C, and cytomegalovirus, as well as anti-bacterials. Notably, Daria led research efforts that identified the first-in-class HIV integrase inhibitor, which won the 2008 Prix Galien award.

Over the course of her esteemed career, Dr. Hazuda has received numerous awards and contributed to over 200 peer-reviewed publications.

Daria trained as a biochemist at the State University of New York at Stony Brook, and went on to complete a postdoctoral research fellowship in the department of immunology at Smith Kline, now known as GSK.